MARKET

MTEM

MTEM

Molecular US
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.29
-0.19
-1.66%
After Hours: 11.25 -0.04 -0.35% 17:27 03/02 EST
OPEN
11.44
PREV CLOSE
11.48
HIGH
11.88
LOW
11.20
VOLUME
205.21K
TURNOVER
--
52 WEEK HIGH
19.12
52 WEEK LOW
7.51
MARKET CAP
631.83M
P/E (TTM)
-5.5608
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Molecular Templates to Participate in Upcoming Virtual Investor Conferences
GlobeNewswire · 4d ago
8-K: Molecular Templates, Inc.
(EDGAR Online via COMTEX) -- NASDAQ false 0001183765 0001183765 2021-02-17 2021-02-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/23 05:01
Gallbladder Cancer Treatment Market Size, Growth, Share 2021 Trends, Forecast by Manufacturers, Regions, Type and Application to 2026
Feb 22, 2021 (The Expresswire) -- Global Gallbladder Cancer Treatment Market 2021 industry research report gives Advancement strategies and plans are talked...
The Express Wire · 02/23 04:49
Significant Insider purchase of Molecular Templates (MTEM) Shares Extends the Buying Trend of Last Quarter
MT Newswires · 02/22 22:34
Newsflash: Molecular Templates, Inc. (NASDAQ:MTEM) Analysts Have Been Trimming Their Revenue Forecasts
Market forces rained on the parade of Molecular Templates, Inc. ( NASDAQ:MTEM ) shareholders today, when the analysts...
Simply Wall St. · 02/21 08:02
Insider Trends: Insider Purchase Continues Molecular Templates Positive Trend
MT Newswires · 02/19 17:34
Hodgkin Lymphoma Treatment Market Growth, Size, Share, Global COVID-19 Impact on Industry Segments, Revenue, 2021 Top Manufacturers and 2027 Forecast Research Report
The Express Wire · 02/19 09:40
DJ Molecular Templates Shares Falter After Stock Offering Prices
Dow Jones · 02/18 16:06
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MTEM. Analyze the recent business situations of Molecular US through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MTEM stock price target is 19.25 with a high estimate of 34.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 154
Institutional Holdings: 30.48M
% Owned: 54.47%
Shares Outstanding: 55.96M
TypeInstitutionsShares
Increased
31
4.63M
New
30
-2.06M
Decreased
34
4.04M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.09%
Pharmaceuticals & Medical Research
-0.90%
Key Executives
Chairman/Director
Harold Selick
President/Chief Operating Officer
Jason Kim
Chief Executive Officer/Chief Scientific Officer/Director
Eric Poma
Chief Financial Officer/Treasurer/Secretary
Adam Cutler
Other
Roger Waltzman
Independent Director
David Hirsch
Independent Director
David Hoffmann
Independent Director
Kevin Lalande
Independent Director
Jonathan Lanfear
Independent Director
Scott Morenstein
Independent Director
Corazon Sanders
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About MTEM
Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company’s lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.

Webull offers kinds of Molecular Templates Inc stock information, including NASDAQ:MTEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTEM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MTEM stock methods without spending real money on the virtual paper trading platform.